(Q43643250)

English

Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival

scientific article published in August 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

prostate cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Hideyuki Akaza

1

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Shiro Hinotsu

2

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Michiyuki Usami

3

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Yoichi Arai

4

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Hiroshi Kanetake

5

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Seiji Naito

6

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Yoshihiko Hirao

7

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Study Group for the Combined Androgen Blockade Therapy of Prostate Cancer

8

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

language of work or name

0 references

publication date

1 August 2009

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

115

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

3437-3445

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24395

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24395

7 January 2021

based on heuristic

inferred from DOI database lookup

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24395

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24395

7 January 2021

based on heuristic

inferred from DOI database lookup

Tolerability of Antiandrogens in the Treatment of Prostate Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24395

7 January 2021

based on heuristic

inferred from DOI database lookup

A re-assessment of the role of combined androgen blockade for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24395

7 January 2021

based on heuristic

inferred from DOI database lookup

Design and analysis of non-inferiority mortality trials in oncology.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24395

7 January 2021

based on heuristic

inferred from DOI database lookup

Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24395

7 January 2021

based on heuristic

inferred from DOI database lookup

Bicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multicenter trial in Japanese patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24395

7 January 2021

based on heuristic

inferred from DOI database lookup

Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24395

7 January 2021

based on heuristic

inferred from DOI database lookup

Current status and prospects of androgen depletion therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24395

7 January 2021

based on heuristic

inferred from DOI database lookup

The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials. European Organization for Research and Treatment of Cancer (EORTC) Genito-Urinary Tract Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24395

7 January 2021

based on heuristic

inferred from DOI database lookup

Prostate-specific antigen dynamics predict risk of progression in advanced prostate cancer treated with bicalutamide plus castration

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24395

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of quality of life in patients with previously untreated advanced prostate cancer receiving maximum androgen blockade therapy or LHRHa monotherapy: a multicenter, randomized, double-blind, comparative study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24395

7 January 2021

based on heuristic

inferred from DOI database lookup

Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24395

7 January 2021

based on heuristic

inferred from DOI database lookup

The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24395

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.24395

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43643250&oldid=2102279346"